iBio, Inc. — Cyborg Score 6/10

Strategic Profile

iBio has two lead programs: IBIO-610, its activin E antibody, and IBIO-600, its myostatin antibody, both advancing toward human clinical trials with IBIO-610 on track for early 2027 and IBIO-600 planned for H1 2026. IBIO-610 has demonstrated a predicted human half-life of up to 100 days supporting potential dosing as infrequently as twice per year, positioning it as a first-in-class obesity therapeutic with distinct advantages over current GLP-1 treatments.

Cyborg Score Rationale

iBio reported FY2025 revenue of $400,000 with improving unit economics (losses decreased 26.22% to -$18.38M). The company maintains strong preclinical progress with lead assets advancing rapidly while facing typical biotech risks: early-stage programs, capital intensity, and regulatory uncertainties. Analyst consensus rates IBIO as "Strong Buy" with 12-month target of $4.0.

Top Insights

• Secured $24.4M from PIPE financing in January 2026, extending cash runway into Q3 FY2028
• IBIO-610 showed 100-day predicted half-life enabling twice-yearly dosing vs. weekly GLP-1 dosing
• Partnership with AstralBio for obesity and cardiometabolic antibody discovery
• Lean team of 20 employees focused on AI-driven antibody platform

Named Competitors

• Ozempic / Wegovy — Weekly GLP-1 agonist for diabetes and obesity
• Mounjaro / Zepbound — Weekly GLP-1/GIP agonist for diabetes and obesity
• Amgen Obesity Pipeline — MariTide and other GLP-1 programs in development

Recent Developments

• (Feb 2026) Q2 FY2026 results: $26M private placement closed; IBIO-610 and IBIO-600 advancing on track for 2026-2027 clinical trials
• (Jan 2026) Secured additional $24.4M PIPE financing from Frazier Life Sciences
• (Dec 2025) Presented non-human primate data for IBIO-610 at obesity therapeutics conferences; 100-day half-life demonstrated
• (Nov 2025) Regained Nasdaq compliance following public offering

Open the full interactive iBio, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.